Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf

View original at globenewswire.com
Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Integer had strong visibility into customer demand despite experiencing sustained deterioration in sales of two EP devices

    80% confidence
  • CarMax overstated its growth prospects when earlier growth in fiscal year 2026 was temporary benefit from customers buying cars due to tariff speculation

    80% confidence
  • Integer overstated its competitive position within the growing EP manufacturing market

    80% confidence
  • Integer's EP devices were a long-term growth driver for the company's C&V segment

    80% confidence
  • Demand for Inspire V was high

    80% confidence
  • Inspire Medical satisfied all regulatory, technical, and commercial conditions for launch of Inspire V

    80% confidence
  • Lifecore maintained deficient internal controls over financial reporting

    80% confidence
  • Lifecore's remediation efforts with respect to internal control deficiencies were ineffective

    80% confidence
  • Commercial launch of Inspire V was proceeding successfully

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Important Notice to Long-Term Shareholders of CarMax, Inc. (NYSE: KMX); Inspire Medical Systems, Inc. (NYSE: INSP); Integer Holdings Corp. (NYSE: ITGR); Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf — Source | Via News | Finance Via News